Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Sigilon Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/15/2023 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Unknown transaction of 683,760 shares
@ $14.92, valued at
$10.2M
Unknown transaction of 113,960 shares
@ $14.92, valued at
$1.7M
|
|
| 08/14/2023 |
SC 13D/A
| ELI LILLY & Co reports a 100% stake in Sigilon Therapeutics, Inc. |
| 08/14/2023 |
4
| ELI LILLY & Co (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Bought 1,718,493 shares
@ $14.92, valued at
$25.6M
|
|
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/11/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 08/11/2023 |
4
| Cole Douglas G. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Oesterle Stephen N. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
Disposed/sold 4,273 options to buy
@ $7.51, valued at
$32.1k
|
|
| 08/11/2023 |
4
| Shaff Eric D. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| RUFFOLO ROBERT R (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
Disposed/sold 3,754 options to buy
@ $7.51, valued at
$28.2k
|
|
| 08/11/2023 |
4
| Cox John (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 341 shares
@ $0
Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Kowalsky Matthew Paul (CHIEF OF STAFF AND CLO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 1,925 shares
@ $0
Disposed/sold 12,690 options to buy
@ $0.75, valued at
$9.5k
|
|
| 08/11/2023 |
4
| Patel Kavita (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Ashton-Rickardt Philip (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 8,845 options to buy
@ $0.75, valued at
$6.6k
|
|
| 08/11/2023 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 2,884 shares
@ $0
Disposed/sold 8,846 options to buy
@ $0.75, valued at
$6.6k
|
|
| 08/11/2023 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 12,169 shares
@ $0
Disposed/sold 35,382 options to buy
@ $0.75, valued at
$26.5k
|
|
| 08/11/2023 |
4
| Pontes Josias (CFO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 3,504 shares
@ $0
Disposed/sold 10,767 options to buy
@ $0.75, valued at
$8.1k
|
|
| 08/11/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/10/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/10/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/01/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/27/2023 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Exercised 2,884 options to buy
@ $19.24, valued at
$55.5k
|
|
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/18/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/13/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
|
|
|